IDH1 mutations in oligodendroglial tumors: Comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR

Brain Pathology

Volumn 23, Issue 3, 2013, Pages 285-293

  Lee, Dakeun ^b   Suh, Yeon Lim ^a   Kang, So Young ^a   Park, Tae In ^b   Jeong, Ji Yun ^b   Kim, Se Hoon ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

isocitrate dehydrogenase 1; oligodendroglial tumors; PNA mediated clamping PCR; pyrosequencing

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; PEPTIDE NUCLEIC ACID;

ARTICLE; ASTROCYTOMA; CLAMPING POLYMERASE CHAIN REACTION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NESTED POLYMERASE CHAIN REACTION; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

BRAIN NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MUTATION; OLIGODENDROGLIA; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS;

EID: 84876283937     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12000     Document Type: Article

References (32)

1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von, Deimling A, (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (Berl) 116: 597-602.
2. Beau-Faller M, Legrain M, Voegeli AC, Guerin E, Lavaux T, Ruppert AM, et al (2009) Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer 100: 985-992.
3. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333: 1453-1455.
4. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, et al (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol (Berl) 121: 241-252.
5. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462. pp. 739-744.
6. Eberhard DA, Giaccone G, Johnson BE, (2008) Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26: 983-994.
7. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel MC, Reifenberger G, (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol (Berl) 119: 501-507.
8. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207: 339-344.
9. Han HS, Lim SN, An JY, Lee KM, Choe KH, Lee KH, et al (2012) Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol 7: 355-364.
10. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (Berl) 120: 707-718.
11. Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN, (2010) Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 12: 487-492.
12. Ichimura K, (2012) Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol 29: 131-139.
13. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW, (2002) Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32: 1185-1196.
14. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (eds) (2007) WHO Classification of Tumors of the Central Nervous System. IARC: Lyon.
15. Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, et al (2010) PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20: 298-300.
16. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303.
17. Nagai Y, Miyazawa H, Huqun TT, Udagawa K, Kato M, Fukuyama S, et al (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282.
18. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
19. Orum H, Nielsen PE, Egholm M, Berg RH, Buchardt O, Stanley C, (1993) Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res 21: 5332-5336.
20. Pao W, Ladanyi M, (2007) Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13: 4954-4955.
21. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
22. Perizzolo M, Winkfein B, Hui S, Krulicki W, Chan JA, Demetrick DJ, (2012) IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension. Brain Pathol 22: 619-624.
23. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191-196.
24. Preusser M, Wohrer A, Stary S, Hoftberger R, Streubel B, Hainfellner JA, (2011) Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 70: 715-723.
25. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al (2009) Isocitrate dehydrogenase 1 con 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154.
26. Sutani A, Nagai Y, Udagawa K, Uchida Y, Koyama N, Murayama Y, et al (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95: 1483-1489.
27. Taback B, Bilchik AJ, Saha S, Nakayama T, Wiese DA, Turner RR, et al (2004) Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 111: 409-414.
28. Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, et al (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28: 115-123.
29. Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A, et al (2007) Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 98: 246-252.
30. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H, (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153.
31. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, et al (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226: 7-16.
32. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324: 261-265.